Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up – Time to Buy?

Apogee Therapeutics Inc. (NASDAQ:APGE) gapped up before the market opened on Monday . The stock had previously closed at $66.04, but opened at $77.32. Apogee Therapeutics shares last traded at $78.3550, with a volume of 1,135,672 shares changing hands.

Key Headlines Impacting Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 Part A data for zumilokibart (APG777) showed durable maintenance and deepening of responses with every‑3‑month and every‑6‑month dosing (e.g., 75% and 85% maintained EASI‑75), supporting the drug’s infrequent‑dosing value proposition. GlobeNewswire: 52‑Week Data
• Positive Sentiment: Analysts reacted quickly with multiple buy ratings and big price‑target increases (Guggenheim, Canaccord, Citi, BTIG), lifting sentiment that the program could support late‑stage development or M&A interest. Benzinga: Analyst Upgrades
• Positive Sentiment: Investor write‑ups and media coverage highlighted the favorable maintenance results and potential next catalysts (Part B induction data in Q2 and possible phase‑3 start in H2 2026), sustaining bullish narrative. Seeking Alpha: Strong Buy / Catalyst Summary
• Neutral Sentiment: Company held a conference call/webcast to review the Part A 52‑week data, providing more transparency on durability and safety that investors can digest for modeling. GlobeNewswire: Conference Call
• Neutral Sentiment: Short‑interest notices in the feed show zero reported short shares (likely a data artifact); they do not provide meaningful evidence of positioning pressure.
• Negative Sentiment: Apogee announced a proposed $300 million underwritten public offering (with up to $45M option), which raises dilution risk and often triggers selling pressure after a rally — the most likely proximate cause of the intraday pullback. GlobeNewswire: Offering Announcement

Analysts Set New Price Targets

A number of brokerages recently commented on APGE. Citigroup boosted their target price on Apogee Therapeutics from $95.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank Of Canada cut their price target on Apogee Therapeutics from $83.00 to $82.00 and set a “sector perform” rating on the stock in a report on Monday, March 2nd. Guggenheim raised their price objective on Apogee Therapeutics from $130.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush boosted their price objective on Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. Finally, UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 7th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Apogee Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $110.43.

Apogee Therapeutics Stock Performance

The company has a market cap of $5.07 billion, a price-to-earnings ratio of -17.30 and a beta of 1.39. The stock’s fifty day moving average is $71.16 and its two-hundred day moving average is $63.95.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.02. On average, equities research analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Insider Activity

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the sale, the chief executive officer directly owned 1,152,987 shares of the company’s stock, valued at approximately $86,220,367.86. This represents a 1.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total value of $133,525,000.00. Following the transaction, the director owned 298,647 shares in the company, valued at approximately $22,786,766.10. This trade represents a 85.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,839,700 shares of company stock worth $140,118,083 over the last 90 days. 42.77% of the stock is currently owned by corporate insiders.

Institutional Trading of Apogee Therapeutics

Several institutional investors have recently made changes to their positions in APGE. Wellington Management Group LLP lifted its position in shares of Apogee Therapeutics by 0.5% during the fourth quarter. Wellington Management Group LLP now owns 4,746,585 shares of the company’s stock valued at $358,272,000 after purchasing an additional 22,884 shares in the last quarter. Vanguard Group Inc. grew its position in Apogee Therapeutics by 27.3% in the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company’s stock worth $215,709,000 after purchasing an additional 612,193 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Apogee Therapeutics by 189,522.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,732,456 shares of the company’s stock worth $206,246,000 after purchasing an additional 2,731,015 shares in the last quarter. Perceptive Advisors LLC increased its stake in Apogee Therapeutics by 72.4% in the 4th quarter. Perceptive Advisors LLC now owns 2,330,651 shares of the company’s stock valued at $175,918,000 after buying an additional 978,662 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in Apogee Therapeutics by 324.4% in the 4th quarter. Janus Henderson Group PLC now owns 2,062,604 shares of the company’s stock valued at $155,697,000 after buying an additional 1,576,626 shares during the last quarter. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.